Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$1.71B |
| 2 |
Eli Lilly
LLY
|
+$1.55B |
| 3 |
Tesla
TSLA
|
+$1.14B |
| 4 |
Boeing
BA
|
+$935M |
| 5 |
TE Connectivity
TEL
|
+$910M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.79B |
| 2 |
Visa
V
|
+$1.57B |
| 3 |
General Dynamics
GD
|
+$1.55B |
| 4 |
Morgan Stanley
MS
|
+$1.29B |
| 5 |
Exelon
EXC
|
+$1.15B |
Sector Composition
| 1 | Technology | 24.19% |
| 2 | Healthcare | 17.87% |
| 3 | Financials | 14.67% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Solventum
SOLV
$12.7B
| $562K | ﹤0.01% |
8,504
+1,571
| +23% | +$104K |
|
1702
Nkarta
NKTX
$140M
| $561K | ﹤0.01% |
225,224
+8,883
| +4% | +$22.1K |
|
|
INZY
1703
DELISTED
Inozyme Pharma
INZY
| $555K | ﹤0.01% |
200,336
-60,383
| -23% | -$167K |
|
1704
Korro Bio
KRRO
$289M
| $554K | ﹤0.01% |
14,553
+1,501
| +12% | +$57.1K |
|
1705
Lexicon Pharmaceuticals
LXRX
$418M
| $552K | ﹤0.01% |
747,996
+15,249
| +2% | +$11.3K |
|
1706
iShares MSCI Canada ETF
EWC
$3.26B
| $550K | ﹤0.01% |
13,640
+3,163
| +30% | +$127K |
|
1707
Aurinia Pharmaceuticals
AUPH
$1.68B
| $546K | ﹤0.01% |
+60,751
| New | +$546K |
|
1708
Ardelyx
ARDX
$1.59B
| $544K | ﹤0.01% |
107,345
-10,925
| -9% | -$55.4K |
|
1709
Elastic
ESTC
$9.3B
| $536K | ﹤0.01% |
5,414
-3,720
| -41% | -$369K |
|
1710
Abeona Therapeutics
ABEO
$330M
| $520K | ﹤0.01% |
+93,289
| New | +$520K |
|
1711
Novavax
NVAX
$1.3B
| $519K | ﹤0.01% |
64,538
-8,577
| -12% | -$69K |
|
1712
Lexeo Therapeutics
LXEO
$280M
| $507K | ﹤0.01% |
76,981
+25,089
| +48% | +$165K |
|
1713
Jack Henry & Associates
JKHY
$11.7B
| $506K | ﹤0.01% |
2,886
+423
| +17% | +$74.2K |
|
1714
ADC Therapeutics
ADCT
$372M
| $504K | ﹤0.01% |
253,342
+84,785
| +50% | +$169K |
|
1715
Solid Biosciences
SLDB
$420M
| $498K | ﹤0.01% |
124,551
+4,747
| +4% | +$19K |
|
1716
Neurogene
NGNE
$271M
| $496K | ﹤0.01% |
21,717
+3,427
| +19% | +$78.3K |
|
1717
Organon & Co
OGN
$2.77B
| $492K | ﹤0.01% |
32,966
+10,108
| +44% | +$151K |
|
1718
BioMarin Pharmaceuticals
BMRN
$10.4B
| $490K | ﹤0.01% |
7,461
+402
| +6% | +$26.4K |
|
1719
Best Buy
BBY
$15.9B
| $488K | ﹤0.01% |
5,683
+3,354
| +144% | +$288K |
|
1720
Nektar Therapeutics
NKTR
$926M
| $486K | ﹤0.01% |
34,827
+3,288
| +10% | +$45.9K |
|
1721
Henry Schein
HSIC
$8.37B
| $478K | ﹤0.01% |
6,902
+775
| +13% | +$53.6K |
|
1722
Black Diamond Therapeutics
BDTX
$185M
| $473K | ﹤0.01% |
221,236
+16,279
| +8% | +$34.8K |
|
1723
Royalty Pharma
RPRX
$15.7B
| $473K | ﹤0.01% |
18,539
+733
| +4% | +$18.7K |
|
1724
Arrow Electronics
ARW
$6.61B
| $464K | ﹤0.01% |
4,100
+168
| +4% | +$19K |
|
1725
Larimar Therapeutics
LRMR
$336M
| $449K | ﹤0.01% |
116,067
+10,821
| +10% | +$41.9K |
|